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INTRODUCTION
Transarterial radioembolization (TARE), using yttrium-90 
(90Y) microspheres, is a treatment option for hepatocellular 
carcinoma (HCC) (1, 2) particularly in intermediate and 
advanced stages. It produces disease control rates of 
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77–90% and is usually well-tolerated (3). Although TARE 
is increasingly popular, the imaging criteria best suited for 
assessing tumor response to TARE remain unknown.
Response Evaluation Criteria in Solid Tumors (RECIST) 
were considered the standard for evaluation of solid 
tumors, which defines responses according to changes 
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in the target lesion size during imaging assessment (4). 
However, size metrics can be misleading when applied to 
locoregional therapies in HCC. Thus, the modified RECIST 
criteria (mRECIST) for HCC consider changes in the degree 
of tumor arterial enhancement (5). Response evaluation 
for TARE is difficult, particularly early during follow-up, 
as tumors shrink relatively slowly after TARE, and arterial 
enhancement decreases also require a long time before 
becoming observable (6, 7). RECIST or mRECIST may thus 
not be adequate for assessment of the early response in 
TARE-treated HCC. Additional imaging predictors are needed 
for evaluating prognosis post-TARE. 
Radiation reaction can lead to veno-occlusive disease of 
the liver at 1–3 months after external radiation therapy, 
and at this stage, portal venous phase or delayed-phase 
hyperenhancement on computed tomography (CT) is 
commonly seen due to decreased contrast clearance (8, 
9). Similar to external radiation, TARE can cause regional 
abnormal enhancement, corresponding to veno-occlusive 
changes (9). Although the therapeutic mechanism of action 
of TARE is not clearly understood, radiation reaction and 
necrosis induced by radioembolized material may play a 
major role. Thus, we postulated that a larger combined 
delayed-enhancing area and necrotic area (DN) in the 
tumor-containing segment could be a predictive imaging 
marker of favorable treatment response during early post-
TARE follow-up. However, visual assessment is not suitable 
for differentiation of the delayed-enhancing area, due to 
its low contrast and the heterogeneous enhancement of the 
baseline cirrhotic liver. Therefore, we devised a quantitative 
method for measuring the DN in the tumor-containing 
segment. 
This study aimed to identify an imaging predictor for 
assessment of early treatment responses to TARE in patients 
with HCC, using quantitative assessment of dynamic CT images.
MATERIALS AND METHODS
This study was approved by the Institutional Review 
Board of our institute, and informed consent was waived 
due to the study’s retrospective nature.
Patients
The records of patients who were treated with 90Y-TARE for 
HCC at our institute from April 2011 until March 2016 were 
reviewed. Ninety-three consecutive patients were identified. 
90Y-TARE was performed in patients with HCC unsuited to 
curative treatments, e.g., surgical resection, local ablative 
therapy (radiofrequency ablation or ethanol injection), and 
liver transplantation. Inclusion criteria included: patient 
age of ≥ 20 years, surgically unresectable HCC, single or 
multifocal measurable HCC without extra-hepatic metastasis, 
Eastern Cooperative Oncology Group performance status of 
0 or 1, Child-Pugh class A or B, and adequate hematological 
(white blood cell count ≥ 2000/µL, hemoglobin level ≥ 10 
g/dL, and platelet count ≥ 105/μL) and renal function (serum 
creatinine ≤ 1.5 mg/dL). The bilirubin cutoff was less than 
2.0 mg/dL, but 3 patients with a bilirubin level exceeding 
the cutoff value were included, because the tumors were 
localized, minimizing normal hepatic parenchymal damage.
Patients were excluded from the study if they 1) had 
insufficient CT data or a period between imaging and the 
procedure exceeding 8 weeks (n = 22), 2) did not undergo a 
second follow-up imaging examination as they were lost to 
follow-up or had expired (n = 9), 3) were not treated with 
resin-based microspheres (n = 15), or 4) had simultaneously 
undergone other treatments (n = 3) (Fig. 1). 
The study population comprised 44 patients (34 men and 
10 women; mean age: 60 ± 12 years; age range: 33–91 years) 
who had undergone dynamic liver CT before and 4 weeks 
post-TARE (Fig. 1). 
TARE with 90Y 
All patients underwent diagnostic angiography for 
Patients who were treated with 90Y-TARE for HCC
• With HCC by imaging or pathologic diagnosis
• With dynamic liver CT scan before and 4 weeks after TARE (n = 44)
Patients who were treated with 90Y-TARE for HCC
between April 2011 and March 2016 (n = 93)
Insufficient CT data or period between imaging
  and procedure exceeding 8 weeks (n = 22)
Resin-based microspheres (SIR-Spheres*) were  
  not used (n = 15)
Simultaneously underwent other treatment  
  (n = 3)
No second follow-up imaging examination  
  as patients were lost to follow-up or had  
  expired (n = 9)
Fig. 1. Flowchart shows inclusion and exclusion criteria 
for present study. *SIR-Spheres; Sirtex Medical. CT = computed 
tomography, HCC = hepatocellular carcinoma, TARE = transarterial 
radioembolization, 90Y = yttrium-90
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evaluating the suitability of the treatment and the dose 
calculation. Celiac, common hepatic arteriography, and 
cone-beam CT arteriography were performed to evaluate the 
tumor feeding artery distribution and to determine the target 
artery of radioembolization. Twelve patients underwent coil 
embolization of the cystic artery (n = 10), the accessory left 
gastric artery (n = 1), and both the right gastric and cystic 
arteries (n = 1), to avoid non-target embolization of 90Y. 
Depending upon the extent of tumor burden, patients were 
treated with either a segmental (n = 12), lobar (n = 20), or 
lobar and segmental (n = 12) approach. Hepato-pulmonary 
shunt was evaluated by injection of technetium-99m-
labeled macroaggregated albumin at the target artery. We 
measured the liver and the tumor volume of each patient 
and the radiation dose was then determined based on the 
planning angiogram and hepato-pulmonary shuntogram, 
using a partition model (10), after calculating the proper 
tumor dose and the safety dose to the lung and normal 
liver. The target-absorbed radiation dose of the normal liver 
and lung was not to exceed 70 Gy and 25 Gy, respectively. 
90Y was prepared in the Nuclear Medicine Department of our 
institution, according to the manufacturer’s preparation 
guide. 90Y-resin microspheres (SIR-Spheres; Sirtex Medical, 
North Sydney, Australia) were infused at the feeding artery 
of the tumor as selectively as possible within 2 weeks after 
planning angiography by using a 3-French microcatheter 
(Terumo, Tokyo, Japan).
CT Imaging Protocol
Four-phase dynamic CT images were obtained before and 
4 weeks post-TARE using the same imaging protocol with 
16-, 64-, or 128-channel multidetector CT scanners. The CT 
scanners used pre- and post-procedure were not necessarily 
the same. First, a pre-contrast CT scan was performed. CT 
was performed after intravenous administration of 1.5–2.0 
mL/kg of iodinated contrast media (300 mg I/mL) for a 
fixed injection duration of 30 seconds (rate, 2–4 mL/s), 
followed by a 20-mL saline chaser bolus injection. Injection 
velocity and duration were adjusted for the individual’s 
vessel condition. Using a bolus-tracking technique, the 
late arterial phase was performed 18 seconds after the 
attenuation value reached 100 HU at the abdominal aorta. 
The portal venous phase and delayed phase were obtained 
with a scan delay of 30 seconds and 150 seconds after the 
end of the previous phase, respectively (Table 1).
Assessment of Response
After radioembolization, tumor progression was defined 
as the emergence of enhanced arterial phase areas, followed 
by washout in the portal phase, or when nodules had 
increased in size during the follow-up. When such patterns 
were observed next to the post-treatment zone, they were 
regarded as local tumor progression (LTP). LTP was reported 
for the largest tumor in each patient. LTP was evaluated 
at each follow-up CT scan, but early treatment response 
was evaluated 4 weeks post-TARE, based on the RECIST, 
mRECIST, and newly proposed quantitative criteria. 
Two board-certified abdominal radiologists (with 20 
and 5 years of experience in abdominal CT, respectively) 
retrospectively and qualitatively analyzed the pre-TARE 
CT images and achieved consensus on the following: the 
largest diameter of the tumor, the largest diameter of the 
arterial enhancing portion (DAE), number of tumors, bilobar 
involvement, portal vein invasion (PVI), and hepatic vein 
invasion. 
Quantitative Analysis
Quantitative analysis was performed using CT images 
Table 1. CT Parameters
Parameters Sensation 16 Sensation 64 SOMATOM Definition Flash Lightspeed VCT Ingenuity
No. of channels 16 64 64 64 128
Section collimation* 16 x 0.75 64 x 0.600 64 x 0.600 64 x 0.625 64 x 0.625
Slice thickness (mm) 3–5 3–5 3–5 3–5 3–5
Pitch 1 0.6 0.6 0.9840 0.9840
Tube current (mAs)† 240 170 170 150–350‡ 127–300§
Rotation time (sec) 0.5 0.5 0.5 0.5 0.5
Tube voltage (kV) 120 100–120 100–120 100–120 100–120
Matrix 512 x 512 512 x 512 512 x 512 512 x 512 512 x 512
Following CT scanners were used: Sensation 16, Sensation 64, and SOMATOM Definition Flash (Siemens Healthineers); Lightspeed VCT (GE 
Healthcare); and Ingenuity (Philips Medical). *Number of detector rows times section thickness (mm), †Reference milliampere-seconds, 
‡Noise index 21.45, §Dose right index 20. CT = computed tomography
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before and 4 weeks post-TARE. Contrast-enhanced dynamic 
CT studies were retrieved from the institutional archive 
and loaded onto a standard workstation in digital imaging 
and communications in medicine format. We subtracted 
the pre-contrast images from the delayed-phase images 
to create the delayed-phase enhancement map (11). The 
delayed-enhancing area was defined as an area with an 
enhancement greater than the mean value + 2 times the 
standard deviation (SD) of the normal liver parenchymal 
enhancement. The necrotic area was defined as an area with 
an enhancement of 20 HU or less in the delayed phase. The 
area below the threshold value of the delayed enhancement 
was removed from the enhancement map. A freehand-drawn 
region of interest (ROI) was placed along the boundary of 
the tumor-containing hepatic segment in the cross-section 
showing the largest diameter of the largest tumor. The ROI 
was drawn for the whole tumor-containing segment, not for 
the tumor boundary, to reflect the peritumoral change after 
treatment and to increase reproducibility. The DN in the ROI 
was measured automatedly (Fig. 2) on images before and 
post-TARE, and differences were calculated. Specifically, 
the increase in the delayed-enhancing area (DI), the 
increase in the necrotic area (NI), and the increase in the 
DN (DNI) in the tumor-containing segment were calculated. 
The percentage increase in these areas (percentage DI 
[pDI], percentage NI [pNI], percentage DNI [pD + N]) 
was calculated, as these are more generalizable to clinical 
practice: percentage increase value = (post-TARE value - pre-
TARE value) / pre-TARE value. All processes were performed 
by an abdominal radiologist with 5-years’ experience, 
using in-house software written in Matlab (version 2017a, 
MathWorks Inc., Natick, MA, USA) (12). Quantitative 
analysis is described in full in the Supplementary Materials 
1 (in the online-only Data Supplement). One additional 
radiologist performed measurement of the pD + N, pDI, and 
pNI to test interreader reproducibility.
Statistical Analysis
The descriptive variables are presented as mean (± SD) 
values or the median and interquartile range (IQR) values 
for non-normally distributed data. Local progression-free 
survival (PFS) was defined as the interval between TARE 
and death, last follow-up imaging, the most recent follow-
up visit, or the date of LTP at post-therapeutic imaging. 
Patients who had undergone liver transplantation were 
censored at the date of transplantation. Patients with 
a lesion that had been additionally treated during the 
follow-up period, based on clinical considerations other 
Fig. 2. Serial steps in quantitative measurement of pD + N pre- and post-TARE, pre-treatment images (A-E), post-treatment images (F-J).
(A, F) Pre-contrast, (B, G) delayed phase, (C, H) subtraction image from pre-contrast and delayed phase images, (D, I) map of delayed 
enhancement after removing area below threshold. Freehand-drawn ROI (yellow dot line) was placed along boundary of tumor-containing hepatic 
segments in map of delayed enhancement (C, H), then software automatically selected same regions in other processed images (D, E, I, J). This 
ROI was commonly used to measure combined delayed-enhancing area and necrotic area in each map. (E, J) map of non–enhancing area. pD + N 
= percentage increase in combined delayed-enhancing area and necrotic area, ROI = region of interest 
A
F
B
G
C
H
D
I
E
J
453
Early Response to Treatment of Hepatocellular Carcinoma with Radioembolization
https://doi.org/10.3348/kjr.2018.0469kjronline.org
than LTP imaging evidence, were censored. Differences 
in PFS between patient groups, based on Kaplan-Meier 
survival curves, were assessed with the log-rank test. Each 
continuous variable was dichotomized to determine the 
optimal cutoff value. This procedure considered all possible 
continuous variables values as potential cutoff points. The 
cutoff corresponding to the largest difference between the 
2 groups was determined based on the log-rank statistic 
(13, 14). Univariate and multivariate Cox regression 
analyses were used for identifying PFS prognostic factors. 
Factors were entered into the multivariate Cox regression 
model using backward stepwise selection with the Akaike 
information criterion, and hazard ratios (HRs) and 95% 
confidence intervals (CIs) were estimated. The interreader 
reproducibility was evaluated in terms of the intraclass 
correlation coefficient (ICC). An ICC value higher than 
0.75 indicates good reproducibility (15, 16). For all tests, 
statistical significance was set at p < 0.05. R (version 3.3.1, 
R Foundation for Statistical Computing, Vienna, Austria) 
was used for all statistical analysis.
RESULTS
Demographics and Patient Disease Characteristics
Patient characteristics are described in Table 2.
The first follow-up CT imaging was performed a median 23 
days (IQR, 21–28 days) post-TARE. The mean diameters of 
the tumors were 8.36 ± 3.07 cm and 7.96 ± 3.37 cm before 
and at the first post-TARE follow-up, respectively, and the 
median diameter decrease was 2.8% (IQR -3.34% to 15.7%). 
The mean DAE in tumors were 7.47 ± 3.26 and 6.58 ± 3.50 
cm before and at the first follow-up, respectively, and the 
median decrease in DAE was 10.2% (IQR 0.0–26.6%). The 
median pD + N was 17.9% (IQR -8.9% to 73.3%), and the 
median pDI and pNI were 28.7% (IQR -25.4% to 106.9%) 
and 12.8% (IQR -39.3% to 105.1%), respectively. At first 
follow-up, 3 (6.8%) and 10 patients (22.7%) showed partial 
response in RECIST and mRECIST, respectively, and all the 
other patients showed stable disease.
Table 2. Baseline Patient and Tumor Characteristics
Variables Values
Ages (years), mean ± SD (range) 60 ± 12 (33–91)
Male:female (%) 34:10 (77:23)
Etiology
Hepatitis B 36 (81.8)
Hepatitis C 4 (9.1)
Hepatitis B and C 1 (2.3)
Alcoholic 1 (2.3)
Cryptogenic 2 (4.5)
Child-Pugh class
A 43 (97.7)
B 1 (2.3)
ECOG
0 26 (59.1)
1 18 (40.9)
Method of HCC diagnosis
Imaging 31 (70.5)
Histopathology 13 (29.5)
Biopsy 3 (6.8)
Resection 9 (20.5)
Transplantation 1 (2.3)
BCLC stage
A 5 (11.4)
B 22 (50.0)
C 17 (38.6)
Tumor size (mean ± SD) (cm) 8.36 ± 3.07
Tumor number 
1–3 32 (72.7)
≥ 4 12 (27.3)
Lobar distribution
Unilobar 28 (63.6)
Bilobar 16 (36.4)
Portal venous invasion 16 (36.4)
Previous HCC therapy
None 42 (95.5)
TACE/TACI 2 (4.5)
Data are presented as numbers and percentage (in parentheses). 
BCLC = Barcelona Clinic Liver Cancer, ECOG = Eastern Cooperative 
Oncology Group performance status, HCC = hepatocellular 
carcinoma, SD = standard deviation, TACE = transcatheter arterial 
chemoembolization, TACI = transcatheter arterial chemoinfusion
Table 3. Univariate Cox Regression Analysis for PFS
Variables HR 95% CI P
DNI 0.999 0.998–0.999 0.033*
pD + N 0.991 0.982–0.999 0.043*
NI 0.999 0.998–1.000 0.079
pNI 0.997 0.992–1.002 0.203
DI 0.999 0.999–1.000 0.250
pDI 0.997 0.994–1.001 0.152
Diameter decrease (%) 0.978 0.936–1.022 0.322
Arterial enhancing portion  
  decrease (%)
0.973 0.936–1.012 0.174
*Statistically significant. CI = confidence interval, DI = increase 
in delayed-enhancing area, DNI = increase in combined delayed-
enhancing area and necrotic area, HR = hazard ratio, NI = increase 
in necrotic area, pD + N = percentage DNI, pDI = percentage DI, 
PFS = local progression-free survival, pNI = percentage NI
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Patient Outcome
Of the 44 treated HCCs, estimated probabilities of PFSs 
were 70.6% and 33.5% for 1-year and 2-year post-TARE, 
respectively. Nine patients (20.5%) underwent hepatic 
resection and 1 (2.3%) had a liver transplantation post-
TARE, with curative intent.
In univariate Cox regression analysis that included DNI, 
NI, DI, pD + N, pNI, pDI, the tumor diameter decrease (%), 
and the DAE decrease (%) as continuous variables, DNI and 
pD + N showed a statistically significant correlation with PFS 
(DNI, HR 0.999, p = 0.033; pD + N, HR 0.991, p = 0.043); 
other variables showed no statistical significance (Table 3).
The optimal cutoff points for predicting PFS were 35.5%, 
-7.1%, 1.4%, and 17.3% for pD + N, pNI, diameter decrease, 
Fig. 3. PFS curves according to parameters of quantitative analysis. DAE = largest diameter of arterial enhancing portion, PFS = local 
progression-free survival, pNI = percentage increase in necrotic area
1 2 3
Time (years)
p = 0.001
# at risk
Higher 17                       8                        2                        1
Lower  27                       3                        0                        0
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p = 0.016
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Lower  15                       4                        0                        0
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Time (years)
p = 0.114
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and DAE decrease, respectively, and each variable was 
dichotomized into 2 groups: those with values ≥ the 
optimal cutoff point, and those with values < the optimal 
cutoff point. In Kaplan-Meier curves, estimated probabilities 
of PFS were 93.0% at 1-year, and 50.0% at 2-years post-
TARE for the higher pD + N group, and 48.9% at 1-year, and 
0% at 2-years post-TARE for the lower pD + N group (median 
PFS, 21.2 months vs. 6.1 months) (Fig. 3). Estimated 
probabilities of PFS were 81.2% at 1-year, and 54.1% at 
2-year post-TARE for the higher pNI group, and 54.2% at 
1-year, and 0% at 2-year post-TARE for the lower pNI group 
(medial PFS, 29.6 months vs. 16.9 months). The PFS of the 
higher pD + N, higher pNI, and higher DAE decrease groups 
was significantly greater than that of the lower groups, 
respectively (pD + N, p = 0.001; pNI, p = 0.016; DAE, p = 
0.038; log-rank test).
In univariate Cox regression analysis, pD + N (lower vs. 
higher, HR 14.8, p = 0.011), pNI (lower vs. higher, HR 4.0, 
p = 0.025) and pre-TARE tumor size (HR 1.2, p = 0.018) 
significantly predicted PFS (Table 4, Fig. 4). In multivariate 
analysis, pD + N (lower vs. higher, HR 17.3, p = 0.009) and 
pre-TARE tumor size (HR 1.3, p = 0.016) were identified as 
independent PFS predictors. 
Measurement on the pD + N, pDI, and pNI showed good 
interreader reproducibility (ICC; 0.77, 0.86, and 0.84, 
respectively).
DISCUSSION
We demonstrated that HCCs with a larger pD + N are less 
likely to develop LTP post-TARE. More specifically, the TARE-
treated HCC lesions with pD + N ≥ 35.5% showed a lower 
probability of PFS than lesions with pD + N < 35.5% (p = 
0.001, log-rank test). Using the optimal pD + N cutoff, we 
could predict a statistically significant difference in PFS at 
the early follow-up in both univariate (HR 14.8, p = 0.011) 
and multivariate analysis (HR 17.3, p = 0.009). Neither the 
RECIST nor mRECIST could predict LTP in the early follow-up 
period. Thus, pD + N, with an optimal cutoff point, could be 
used as a predictor for evaluating early responses to TARE. 
Radioembolization for hepatic tumor treatment 
produces some changes, e.g., necrosis, initial paradoxical 
enlargement, and regions of abnormal enhancement 
corresponding to veno-occlusive changes in the irradiated 
vascular territory (9, 17). This is similar to focal active 
radiation reaction, usually seen as delayed enhancement 
upon external radiation to the liver (8). We therefore 
assumed that the delayed-enhancing area is associated 
with a good prognosis, reflecting an active reaction. Also, 
post-treatment necrosis indicates a good prognosis (5). 
Therefore, we analyzed the correlation of pDI, pNI, and 
pD + N with PFS. pD + N, but not pDI and pNI, correlated 
significantly with good prognosis, possibly because delayed 
Table 4. Results of Cox Regression Analysis for PFS
Variables
Univariate Analysis Multivariate Analysis
HR 95% CI P HR 95% CI P
Optimal pD + N (lower vs. higher) 14.8 1.83–119.10 0.011* 17.3 2.01–148.29 0.009*
Optimal pNI (lower vs. higher) 4.0 1.19–13.33 0.025* N/A N/A N/A
Optimal diameter† 2.4 0.79–7.12 0.125 N/A N/A N/A
Optimal DAE† 3.7 0.99–13.50 0.052 N/A N/A N/A
RECIST, SD (n = 41) vs. PR (n = 3) 0.7 0.09–5.56 0.738 N/A N/A N/A
mRECIST, SD (n = 34) vs. PR (n = 10) 2.1 0.45–9.36 0.354 N/A N/A N/A
Tumor size 1.2 1.04–1.48 0.018* 1.3 1.04–1.51 0.016*
Multiplicity 1.6 0.49–5.10 0.439 N/A N/A N/A
Bilobar 1.7 0.58–5.15 0.329 N/A N/A N/A
PVI 1.8 0.61–5.16 0.294 N/A N/A N/A
HVI 2.4 0.72–8.02 0.152 N/A N/A N/A
Age 1.0 0.92–1.02 0.216 N/A N/A N/A
AFP 1.0 1.00–1.00 0.132 N/A N/A N/A
PIVKA-II 1.0 1.00–1.00 0.370 N/A N/A N/A
Prefix optimal means that following variable was dichotomized by optimal threshold value. *Statistically significant, †Group with 
decreased percentage of diameter or DAE less than optimal threshold value vs. group with higher value. AFP = alpha–fetoprotein, DAE 
= largest diameter of arterial enhancing portion, HVI = hepatic vein invasion, mRECIST = modified RECIST criteria, N/A = not available, 
PIVKA-II = protein induced by vitamin K absence or antagonist II, PR = partial response, PVI = portal vein invasion, RECIST = Response 
Evaluation Criteria in Solid Tumors, SD = stable disease
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enhancement may be transformed into necrosis over time. 
Therefore, measuring the DN may be useful for predicting 
prognosis at each time point.
The currently accepted standard for treatment response 
is tumor size, as determined by RECIST or World Health 
Organization criteria (18, 19). However, assessing 
morphological responses of liver malignancies based on size 
changes may require a long time or may not occur at all 
after local treatment (20). A recent study has shown that 
response evaluation models, including tumor enhancement 
comparisons (mRECIST and European Association for the 
Study of the Liver), more accurately predicted long-term 
survival of transcatheter arterial chemoembolization (TACE)-
treated HCC patients (21). However, it remains controversial 
whether a significant decrease in arterial enhancement 
can be observed by 4 weeks post-TARE for HCC. A decrease 
in arterial enhancement in liver malignancies has been 
reported 4–5 weeks post-TARE or post-TACE (6, 20, 22-
24). Moreover, significant changes in arterial perfusion 
of HCC could not be observed by 4 weeks post-TARE in 
a quantitative analysis of CT perfusion, possibly due to 
differences in the approach to assessing enhancement 
(quantitative versus qualitative) (20). In our study, neither 
the percentage change in diameter nor the DAE correlated 
with PFS, when using continuous values or a cutoff point, 
indicating that RECIST or mRECIST could not predict 
outcomes during the early follow-up period, even though 
the criteria for the percentage of mRECIST were optimized.
It has been proposed that the extent of necrosis post-
TARE could be used for evaluating the early response and 
a combination of necrosis and tumor size could improve 
the accuracy of the response assessment in patients with 
liver metastases (24). However, a relatively long median 
time to response by necrosis criteria was reported in 
post-TARE HCCs, 34 days (95% CI: 29–43 days) (7), and 
response cannot be assessed by 4 weeks. Using pNI with 
an optimal cutoff correlated with PFS in univariate, but 
not in multivariate analysis in our study. Interestingly, in 
the present study, some cases showed a decrease in the 
necrotic area in the image taken 4 weeks after treatment 
(Supplementary Materials 2 in the online-only Data 
Supplement), likely because the initial tumor necrotic area 
Fig. 4. Liver CT images of 53-year-old woman with HCC before TARE (A-D) and 4 weeks after treatment (E-H). 
(A, E) Delayed phase, (B, F) subtraction image from pre-contrast and delayed phase images, (C, G) map of delayed enhancement. (D, H) map 
of necrosis. Measured value of pD + N in tumor-containing segments was 94.9%. Maximal diameter of tumor and maximal DAE in tumor were 
decreased only 1.9% and 2.1%, respectively. Tumor did not recur until 19 months.
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changed to a delayed-enhancing area by contrast-pooling 
with veno-occlusive and inflammatory changes after TARE. 
This finding could be explained by abnormal enhancement 
with paradoxical enlargement, which has been previously 
reported (9, 17). In particular, the post-TARE duration in 
the present study was very short, with a median duration 
of 23 days, suggesting that the early post-TARE change 
seemed to be dominant. 
In the present study, the necrotic area was defined as an 
area showing an enhancement of 20 HU or less. Previously, 
an enhancement of 10 HU or more had been generally used 
as the threshold that defines viability in hepatic tumors 
(24). However, a recent study suggested that the threshold 
of 17.1 HU was the best threshold for the detection of 
pseudoenhancement of the hepatic cyst and that 17.1 HU 
could be used as the cutoff for nonenhancement in necrotic 
HCCs (25). Therefore, in the present study, we used 20 HU 
as the threshold.
Our study has several limitations. First, the number of 
patients is relatively small. The small sample size had the 
potential to mask the weak correlations. Further studies 
with a larger number of patients are needed to ensure 
clinical relevance. Second, histopathological data were 
not available, because most tumors were unresectable at 
diagnosis, or the time between imaging and surgery was 
too long. However, to the best of our knowledge, there 
have been few attempts to evaluate histopathologic change 
within 4 weeks after TARE. Consequently, radiologic findings 
could be more important during the aforementioned period. 
Third, in the presence of multiple tumors, only the largest 
tumor was selected and analyzed to reduce measurement 
errors. Multiple tumors were likely to be intrahepatic 
metastases, and as all tumors were treated in the same 
way, the largest tumor was likely to have a representative 
therapeutic effect. Fourth, a two-dimensional method was 
used for evaluating the quantitative measurement. Tumor 
response after treatment is heterogeneous within the tumor. 
Therefore, tumor response evaluation on a single CT section 
might not be representative of the entire tumor’s response. 
However, in a recent study of apparent diffusion coefficient 
measurement methods for rectal cancer, the diagnostic 
performance of one slice measurement was comparable 
to that of three-dimensional (3D) whole tumor volumetry 
and showed better performance than that of three circular 
ROI measurements (26). Our study is expected to show 
similar results, but further studies on 3D measurement are 
required for accurate measurement. Fifth, the threshold 
value of the delayed enhancement was arbitrary. Because 
2 SD is a commonly used threshold for statistical testing, 
the threshold value of this study was selected to obtain 
the area that was distinct from the surrounding hepatic 
parenchyma, however, further research is needed to 
determine the optimal threshold value.
In conclusion, quantitative analysis of the pD + N in the 
tumor-containing segment in early follow-up after TARE 
may predict PFS in patients with HCC. If the prognosis can 
be predicted in the early follow-up period, such as within 
4 weeks after TARE, we may be able to increase the overall 
survival rate of the patients who are expected to have 
a poor prognosis, by allowing them to prepare for other 
treatments such as liver transplantation.
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